RxDoctor Payments Data

Sanjay Lulla, DO

Cardiovascular Disease · Humble, TXNPI 1700229234

Payments from drug & device makers

$3,028in general payments, 2019–2025

Across 89 payments — averaging $34.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$634
  • Boston Scientific$527
  • Impulse Dynamics (USA) Inc.$267
  • Abiomed$231
  • Abbott$133
  • Pfizer$113
  • plus $1K from 27 others

What the payments were for

  • Travel & lodging$281%
  • Food & beverage$3,00199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,028 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$165,886
Medicare patients
347
Services billed
1,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$103,350
XareltoRivaroxaban46$58,694
EntrestoSacubitril/Valsartan25$28,832
Repatha SyringeEvolocumab21$22,653
Repatha SureclickEvolocumab15$9,472
Atorvastatin Calcium287$3,378
Metoprolol Succinate185$2,038
Losartan Potassium167$1,973
Nifedipine ErNifedipine67$1,957
Ranolazine ErRanolazine15$1,763
Rosuvastatin Calcium93$1,291
Carvedilol189$1,246
Bumetanide42$1,203
Ezetimibe42$1,188
ClopidogrelClopidogrel Bisulfate102$1,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$113$103,35099 claims
Johnson & JohnsonXarelto$62$58,69446 claims
NovartisEntresto$78$28,83225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →